| Title | Role of p53 and Bcl-2 in advanced rectal carcinomas treated with adjuvant therapy |
|---|---|
| Publication Type | Articolo su Rivista peer-reviewed |
| Year of Publication | 2004 |
| Authors | Piperno, G., Cosimelli M., Donnorso R.P., Mancini R., Buglioni S., Novelli Flavia, Sperduti I., Zerbini V., Garufi C., and Mottolese M. |
| Journal | Journal of Chemotherapy |
| Volume | 16 |
| Pagination | 11-14 |
| ISSN | 1120009X |
| Keywords | 80 and over, adult, advanced cancer, aged, antineoplastic agent, cancer adjuvant therapy, cancer staging, cancer survival, colon cancer, conference paper, Female, fluorouracil, folinic acid, high risk patient, human, human tissue, Humans, immunohistochemistry, irinotecan, major clinical study, male, Middle Aged, Neoplasm Staging, oxaliplatin, protein bcl 2, protein p53, Proto-Oncogene Proteins c-bcl-2, Rectal Neoplasms, rectum carcinoma, survival rate, treatment outcome, Tumor Suppressor Protein p53 |
| Abstract | Rectal adenocarcinomas is usually associated to a poorer outcome than colon cancers. In this study we analyzed the impact on overall survival of p53 and Bcl-2, evaluated by immunohistochemical techniques, in 126 advanced rectal cancer patients submitted to 5 fluorouracil based adjuvant therapy. Shorter overall survival was observed in patients bearing p53 positive and Bcl-2 negative tumors, although in multivariate analysis only p53 emerged as independent predictor of a worse outcome. These results seem to indicate that, in stage III-IV rectal cancer, p53 alterations may identify high risk patients to be enrolled in more aggressive and/or innovative adjuvant/neoadjuvant treatments. |
| Notes | cited By 0 |
| URL | https://www.scopus.com/inward/record.uri?eid=2-s2.0-19944427939&partnerID=40&md5=bf380ade740fa4b97363c572d6d18a0b |
| Citation Key | Piperno200411 |
